Description
The Ber-ACT8 monoclonal antibody specifically binds to the human mucosal lymphocyte antigen 1 (HML-1). This is a 175 kDa type I transmembrane glycoprotein, also known as integrin αE (ITGAE, Integrin alpha-E) and CD103. It is found on >90% of intestinal intraepithelial lymphocytes (iIEL) associated with integrin β7. CD103 is also expressed on lamina propria T lymphocytes in the intestine and on phytohemagglutinin-stimulated peripheral blood lymphocytes. It is rarely expressed on resting peripheral blood lymphocytes. It has been suggested that CD103 may have an accessory function for activation of iIEL. CD103 has been reported as a useful tool in hairy cell leukemia research.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
8. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
9. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
10. An isotype control should be used at the same concentration as the antibody of interest.
11. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
12. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
Specifications

General

SourceHuman Slit2-N, amino acids Gln26-Val1118 (Accession# O94813) was expressed in HEK293.
Molecular MassThe 1093 amino acid recombinant protein has a predicted molecular mass of approximately 122.3 kD. The protein migrates at 120.0-140.0 kD under reducing condition by SDS-PAGE. The predicted N-terminal amino acid is Gln.
Purity>98%, as determined by SDS-PAGE gel and HPLC analysis.
FormulationLyophilized from 0.2 µm filtered protein solution with no additives.
Endotoxin LevelLess than 1 EU per µg protein as determined by the LAL method.
Storage & HandlingUnopened vial can be stored at -20°C or -70°C. For maximum results, quick spin vial prior to opening. Reconstitute in 20 mM Tris, 150 mM NaCl, pH 8.8 to a concentration of 0.1-0.5 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein such as 0.1% BSA and store working aliquots at -20°C to -80°C. Avoid repeated freeze/thaw cycles.
ActivityImmobilized protein enhances neurite outgrowth at 2.5 - 10 µg/mL.
ApplicationBioassay
DistributionFetal lung and kidney, and adult spinal cord. Weak expression in adult adrenal gland, thyroid, trachea.
FunctionAxon guidance, branching, arborization, neuronal and leukocyte migration.
InteractionCommissural axon, Olfactory bulb axon, CNS sensory neurons, and leukocyte.
Ligand/ReceptorROBO-1, ROBO-2, ROBO-3, Laminin-1, DAN, Gremlin, Glypican-1.
BioactivityMeasured by the ability of immobilized human Slit2-N to enhance neurite outgrowth from E18 rat cortical neurons.
Biology AreaCell Biology, Neuroscience, Synaptic Biology
Molecular FamilyCytokines/Chemokines, Growth Factors
Antigen References1. Brose K, et al. 1999. Cell 96:795-806. 2. Kidd T, et al. 1999. Cell 96:785-794. 3. Wu W, et al. 1999. Nature 400:331-336. 4. Stein E, et al. 2001. Science 291:1928-1938. 5. Bagri A, et al. 2002. Neuron 33:233-248. 6. Plump AS, et al. 2002. Neuron 33:219-232. 7. Grieshammer U, et al. 2004. Dev. Cell 6:709-717. 8. Zhou WJ, et al. 2013. Nature 501:107-111. 9. Rama N, et al. 2015. Nat. Med. 21:483-491.
Gene ID9353
UniProtView information about Slit2-N on UniProt.org
Regulatory StatusRUO
Other NamesSLIL3, Slit homolog 2, Slit Guidance Ligand
BD 757102 RB705 Mouse Anti-Human CD103 Ber-ACT8 | IRIGHT